• Explore /
  • Poster
  • / A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.

A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.

Abstract Video & Slides Poster

Authors

null

Andrew Mark Haydon

Alfred Health, Melbourne, VIC, Australia

Andrew Mark Haydon , Ganessan Kichenadasse , John M. Kirkwood , Howard E. Kaufman , Elizabeth Iannotti Buchbinder , Vinod Ganju , Minal A. Barve , Haifang Jiang , Huinan Xu , Xusha Zhou , Huan J. Zhu , Dongyao Ni , Jiaxin Niu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT04370587

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2526)

DOI

10.1200/JCO.2021.39.15_suppl.2526

Abstract #

2526

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jiaxin Niu

First Author: Breelyn A. Wilky

First Author: Judy S. Wang

First Author: Gonzalo Tapia